share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  10/01 05:14
牛牛AI助理已提取核心訊息
On September 30, 2024, Clene Inc., along with its wholly owned subsidiary Clene Nanomedicine, Inc., entered into a Third Amendment to their existing Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. This amendment modifies the terms of the original loan agreement dated May 21, 2021. The amendment reduces the principal payment due on October 1, 2024, from $3.33 million to $2 million and potentially introduces an interest-only payment period from November 1, 2024, to December 31, 2024, contingent upon the company meeting certain equity funding milestones. Additionally, the amendment outlines repayment terms based on whether Clene Inc. achieves a milestone related to the submission of a New Drug Application for CNM-Au8 for the treatment of ALS to the FDA. Concurrently, the exercise price of warrants issued to Avenue was adjusted from $16.00 to $4.6014 per share. These changes are detailed in the company's filings with the SEC, including the Current Report on Form 8-K and the exhibits attached thereto.
On September 30, 2024, Clene Inc., along with its wholly owned subsidiary Clene Nanomedicine, Inc., entered into a Third Amendment to their existing Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. This amendment modifies the terms of the original loan agreement dated May 21, 2021. The amendment reduces the principal payment due on October 1, 2024, from $3.33 million to $2 million and potentially introduces an interest-only payment period from November 1, 2024, to December 31, 2024, contingent upon the company meeting certain equity funding milestones. Additionally, the amendment outlines repayment terms based on whether Clene Inc. achieves a milestone related to the submission of a New Drug Application for CNM-Au8 for the treatment of ALS to the FDA. Concurrently, the exercise price of warrants issued to Avenue was adjusted from $16.00 to $4.6014 per share. These changes are detailed in the company's filings with the SEC, including the Current Report on Form 8-K and the exhibits attached thereto.
2024年9月30日，Clene Inc.及其全資子公司Clene Nanomedicine, Inc.與Avenue Venture Opportunities Fund, L.P.簽署了《貸款與安防-半導體協議的第三次修正協議》。該修正協議修改了2021年5月21日簽訂的原始貸款協議的條款。修正協議將2024年10月1日到期的本金支付額從$333萬降至$200萬，並可能在2024年11月1日至12月31日期間引入僅利息支付期，前提是公司達到一定的股權融資里程碑。此外，修正協議根據Clene Inc.是否實現與向FDA遞交CNm-Au8治療ALS新藥申請相關的里程碑概述了償還條款。同時，向Avenue發行的認股權行權價格從$16.00調整爲每股$4.6014。這些變更詳細列在公司提交給SEC的文件中，包括報告表單8-k上的當期報告以及附帶的附件。
2024年9月30日，Clene Inc.及其全資子公司Clene Nanomedicine, Inc.與Avenue Venture Opportunities Fund, L.P.簽署了《貸款與安防-半導體協議的第三次修正協議》。該修正協議修改了2021年5月21日簽訂的原始貸款協議的條款。修正協議將2024年10月1日到期的本金支付額從$333萬降至$200萬，並可能在2024年11月1日至12月31日期間引入僅利息支付期，前提是公司達到一定的股權融資里程碑。此外，修正協議根據Clene Inc.是否實現與向FDA遞交CNm-Au8治療ALS新藥申請相關的里程碑概述了償還條款。同時，向Avenue發行的認股權行權價格從$16.00調整爲每股$4.6014。這些變更詳細列在公司提交給SEC的文件中，包括報告表單8-k上的當期報告以及附帶的附件。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

獨立文件3

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。